According to the company, the Epicor LP system has a lower profile as well as other features designed to facilitate easier device introduction and placement around and on patients’s hearts. In addition, the Epicor LP system is said to be equally suited for use in both closed-chest procedures performed through a single incision, and in open-chest procedures.
The first generation Epicor system gained regulatory approval for the treatment of atrial fibrillation (AF) in Europe in 2006. In the US, the first generation Epicor system and the Epicor LP system received clearance from the FDA for the surgical ablation of cardiac tissue but have not been indicated by the FDA specifically for the treatment of AF.